Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wensu Wei
Observed names:
W. Wei,
Wen-su Wei,
WenSu Wei
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Sun Yat-sen University,
Sun Yat-sen University Cancer Center,
Third Xiangya Hospital,
State Key Laboratory of Oncology in South China
ORCID:
0000-0002-8172-3221
Observed ORCID:
0000-0002-8172-3221
OpenAlex ID:
A5070284520
m5C-dependent cross-regulation between nuclear reader ALYREF and writer NSUN2 promotes urothelial bladder cancer malignancy through facilitating RABL6/TK1 mRNAs splicing and stabilization
2023
·
Ning Wang
, Ri-xin Chen
, et al.
·
Cell Death and Disease
·
114
PDF
Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer
2024
·
Minhua Deng
, Zhaohui Zhou
, et al.
·
Advanced Science
·
40
ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
2021
·
Minhua Deng
, Wensu Wei
, et al.
·
Cancer Science
·
35
Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA
2022
·
Chunping Yu
, Yi Zhang
, et al.
·
Biomaterials Research
·
28
PDF
FXR1 can bind with the CFIm25/CFIm68 complex and promote the progression of urothelial carcinoma of the bladder by stabilizing TRAF1 mRNA
2022
·
Minhua Deng
, Ning Wang
, et al.
·
Cell Death and Disease
·
27
PDF
Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
2022
·
Pei Dong
, Xinyue Zhang
, et al.
·
Clinical Cancer Research
·
25
PDF
Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway
2018
·
Gangjun Yuan
, Xin Chen
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
25
PDF
Overexpression of CEP72 Promotes Bladder Urothelial Carcinoma Cell Aggressiveness via Epigenetic CREB-Mediated Induction of SERPINE1
2019
·
XiangDong Li
, Pei Dong
, et al.
·
American Journal Of Pathology
·
23
PDF
Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma
2021
·
Yang Liu
, Zhiling Zhang
, et al.
·
Radiation Oncology
·
16
PDF
Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trial
2023
·
Zhaohui Zhou
, Longbin Xiong
, et al.
·
Cell Reports Medicine
·
14
Neutrophil-to-lymphocyte ratio predicts a poor prognosis for penile cancer with an immunosuppressive tumor microenvironment
2025
·
Xingliang Tan
, Yanjun Wang
, et al.
·
Frontiers in Immunology
·
12
PDF
Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy
2024
·
Tingxuan Huang
, Yulu Peng
, et al.
·
International Immunopharmacology
·
8
Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study
2023
·
Tingxuan Huang
, Jun Wang
, et al.
·
Clinical Genitourinary Cancer
·
8
Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
2022
·
Zeshen Wu
, Yulu Peng
, et al.
·
Cancer Medicine
·
8
Long-term effect of acute ischemic injury on the kidney underwent clamped partial nephrectomy
2023
·
Zhaohui Zhou
, Zhiyong Li
, et al.
·
iScience
·
6
PDF
Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system
2021
·
Zhiyong Li
, Lijuan Jiang
, et al.
·
Cancer Medicine
·
5
PDF
Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report
2016
·
Jingchao Wei
, Xiaoping Zheng
, et al.
·
Oncology Letters
·
5
PDF
First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective study
2026
·
Xi Zhong
, Tingxuan Huang
, et al.
·
Cancer Immunology Immunotherapy
·
4
PDF
3079P Efficacy and safety results from Formula-01: A phrase II study of Disitamab Vedotin plus BCG in HER2 high expression high-risk non-muscle invasive bladder cancer patients (HR-NMIBC)
2025
·
X. Tan
, K. Yao
, et al.
·
Annals of Oncology
·
4
Clinical effectiveness and safety of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): a single-center retrospective study
2025
·
Xi Zhong
, Tingxuan Huang
, et al.
·
World Journal of Urology
·
3
Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma.
2023
·
Yang Liu
, Wensu Wei
, et al.
·
Journal of Clinical Oncology
·
3
PDF
732P Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
2021
·
J. Chen
, W. Wei
, et al.
·
Annals of Oncology
·
3
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.
2024
·
Pei Dong
, Wensu Wei
, et al.
·
Journal of Clinical Oncology
·
1
The role of TROP-2 in the progression and target therapy in penile squamous cell carcinoma.
2024
·
Yi Tang
, Xingliang Tan
, et al.
·
Journal of Clinical Oncology
·
1
215P Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
2023
·
T. Huang
, L. Jiang
, et al.
·
Annals of Oncology
·
1
Show more works
View as search
Works count:
64
Citation count:
422
H-index:
11
I10-index:
11
Year
Topic
Type